Updated:
Andromède
Andromède was established to steward the assets of the Hériard Dubreuil family, whose wealth originates from a controlling interest in the publicly traded...
Andromède
Andromède was established to steward the assets of the Hériard Dubreuil family, whose wealth originates from a controlling interest in the publicly traded spirits group Rémy Cointreau. The firm operates from Paris and represents a concentrated effort to build permanent capital beyond the family's luxury roots. Chairwoman Marie-Amélie de Leusse is the most visible principal, leading the listed entity, while the family office itself pursues a quiet but assertive privately held portfolio. The office invests across private equity, venture capital, and real estate, with a geographic focus on Europe and a technical tilt toward enterprise software, ESG, and deep industrial applications. It favors direct co-investments and special purpose vehicles alongside corporate and institutional partners. The firm backed drone-data platform Delair and its AI-analytics spin-off Alteia alongside Intel and Galia (2018). It also anchored the build-up of European ratings and ESG consultancy EthiFinance, forming an institutional club with Aviva France (2019) and a consortium including Bpifrance, Eiffel Investment Group, and Siparex to consolidate Spread Research. Total assets are undisclosed and estimated at roughly $1.8 billion. The portfolio extends into real assets, including the Verquin Reims Cathédrale hotel. The firm maintains a network of co-investors that includes Intel, AG2R La Mondiale, Klésia, and SMA BTP — a mix of strategic corporates and French institutional allocators that signals a concentrated, club-style operating model rather than a broad fund-of-funds strategy. Philanthropic capital flows through the Fondation de la 2e chance, a separate charitable vehicle. In May 2026, Altss recorded no new operational events, reinforcing a deliberately low public profile. Andromède's structural differentiator is its hybrid posture: a single-family office that assembles institutional-grade club deals around industrial-tech themes, co-investing corporate partners like Intel, and French pension capital under the same SPV without converting into a regulated asset manager. This architecture keeps permanent family capital at the center while pulling external specialist money into its conviction bets.
General information
Firm type
Single Family Office
Year founded
—
AUM
$1.8B (Altss estimate)
Location
Region
Europe
Country
France
City
Paris
Corporate office
Paris, France
Principals
Marie-Amélie de Leusse
Chairwoman of Rémy Cointreau
Sector focus
Frequently asked questions
Who runs investment decisions at Andromède?
Andromède does not publicly name an investment committee or CIO. The most senior disclosed principal is Marie-Amélie de Leusse, who chairs Rémy Cointreau, the listed entity controlled by the family office. Day-to-day investment professionals remain unnamed in available research, reflecting the firm's low-profile operating model.
How does Andromède source proprietary deal flow?
Sourcing appears to rely on long-standing co-investor relationships rather than a public inbound program. The firm has repeatedly co-invested with Intel, Galia, and a recurring club of French institutional investors including Bpifrance, Eiffel Investment Group, and Siparex. This network suggests a conviction-based, partner-driven origination model.
Where does the underlying wealth come from?
The wealth originates from the Hériard Dubreuil family, founders and controlling shareholders of Rémy Cointreau, the publicly traded spirits group behind Rémy Martin cognac and Cointreau liqueur. Andromède operates as the family's private holding and investment vehicle.
Is Andromède structured as a single family office or does it operate more like a venture firm?
It is a single family office, but its investment style mimics a hybrid between a holding company and a club-deal sponsor. Andromède frequently assembles special purpose vehicles and direct co-investments that include non-family institutional investors like Aviva France and Intel, blurring the line between pure SFO and co-investment fund.
What is Andromède's known posture on co-investments alongside external GPs?
Andromède actively participates in direct co-investments and SPVs, often as an anchor alongside other institutional limited partners. It does not appear to commit to blind-pool third-party funds as a primary strategy, preferring to structure deals where it can share governance with a small circle of known partners.
Does Andromède maintain philanthropic structures, and how are they separated?
Yes, the family operates the Fondation de la 2e chance, a separate philanthropic foundation. The foundation is legally distinct from the family office's investment activities, which center on equity positions in industrial tech, robotics, and ESG services firms.
How is Andromède related to Rémy Cointreau?
Andromède is the family office and holding vehicle for the Hériard Dubreuil family, which owns a controlling stake in Rémy Cointreau, one of the world's largest publicly traded spirits companies. Marie-Amélie de Leusse serves as Chairwoman of the board of Rémy Cointreau, directly connecting the family office to the listed entity's governance.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: